Background
In patients with chronic hepatitis C (CHC), liver fibrosis is a complex process, not completely understood, resulting from the activation of hepatic stellate cells and a proinflammatory status.
We aimed to evaluate the inflammation patterns in patients with CHC and the correlations between the inflammatory biomarkers and liver fibrosis.
Methods
We performed a cross-sectional study on patients with CHC, in a tertiary-care hospital in November 2011 -April 2012. We staged liver fibrosis using FibroMax (BioPredictive) and we used CobasTaqman (Roche) for HCV-RNA quantification. Patients were also evaluated by ALT, platelets, erythrocyte sedimentation rate (ESR), fibrinogen, C-reactive protein (CRP) and tumor necrosis factor alpha (TNFa) plasma levels. For TNFa quantification we used Kamiya Biomedical Company ELISA kits.
Results
We enrolled 76 patients with CHC (sex ratio M/F 0.6/1, median age 51 [44-58] years). According to the FibroMax evaluation, most of the patients had F0 fibrosis (25%, n=19), F2 fibrosis (42%, n=32) and F4 fibrosis (16%, n=12) respectively. The median HCV-RNA was 5 [5-5.75] log 10 . History of previous HCV-therapy with pegIFN and ribavirin was recorded in 75% (n=57) of patients and half of them had a sustained virological response.
The inflammatory biomarkers displayed the following patterns: median ESR 12 [8-22.5] 
Conclusion
In patients with CHC, liver fibrosis is correlated with the levels of TNFa, as a biomarker of systemic inflammation.
